Sara C. M. Stoof

Sara C. M. Stoof

Auto-generated profile, based on publicly available information

Sara C. M. Stoof

Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2015 in Haemophilia
Verified
Journal Article
Closed access
PDF file
SSS. C. M. Stoof
S. C. M. Stoof
HSH. W. van Steenbergen
H. W. van Steenbergen
AZA. Zwagemaker
A. Zwagemaker
YSY. V. Sanders
Y. V. Sanders
SCS. C. Cannegieter
S. C. Cannegieter
JEJeroen Eikenboom
Jeroen Eikenboom

2 June 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
KDKatrijn Daenen
Katrijn Daenen
JHJilske A Huijben
Jilske A Huijben
ABAnders Boyd
Anders Boyd
LBLieuwe Bos
Lieuwe Bos
SSSara C M Stoof
Sara C M Stoof
PGPRoVENT- and PRoAcT-COVID Collaborative Group
PRoVENT- and PRoAcT-COVID Collaborative Group
Background: In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. Objective: Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. Methods: This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. Results: As of April 2023, data have been collected for a total of 1500 patients, with data collection anticipated to be completed by December 2023. We expect the first results to be available in early 2024. Conclusions: This study protocol presents a strategy to investigate the effect of high-dose corticosteroids throughout the entire clinical course of hospitalized patients with COVID-19, from hospital admission to the ward or intensive care unit until hospital discharge. Moreover, our exploration of biomarker and gene expression profiles for targeted corticosteroid therapy represents a first step towards personalized COVID-19 corticosteroid treatment. Trial Registration: ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359 International Registered Report Identifier (IRRID): DERR1-10.2196/48183

23 January 2025 in CHEST Critical Care
Verified
Journal Article
Open access
KDKatrijn Daenen
Katrijn Daenen
SSSara C.M. Stoof
Sara C.M. Stoof
HWHugo van Willigen
Hugo van Willigen
ABAnders Boyd
Anders Boyd
VDVirgil A.S.H. Dalm
Virgil A.S.H. Dalm
JHJilske A. Huijben
Jilske A. Huijben

21 June 2017 in Haemophilia
Verified
Journal Article
Closed access
PDF file
SSS. C. M. Stoof
S. C. M. Stoof
LSL. M. Schütte
L. M. Schütte
FLF. W. G. Leebeek
F. W. G. Leebeek
MCM. H. Cnossen
M. H. Cnossen
MKMarieke Kruip
Marieke Kruip

12 May 2017 in Haemophilia
Verified
Journal Article
Closed access
PDF file
SSS. C. M. Stoof
S. C. M. Stoof
DHD. Hodgins
D. Hodgins
FLF. W. G. Leebeek
F. W. G. Leebeek
MCM. H. Cnossen
M. H. Cnossen
HHH. L. D. Horemans
H. L. D. Horemans
MKMarieke Kruip
Marieke Kruip

26 April 2026 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
KDKatrijn Daenen
Katrijn Daenen
ABAnders Boyd
Anders Boyd
VDVirgil A. S. H. Dalm
Virgil A. S. H. Dalm
JHJilske A. Huijben
Jilske A. Huijben
SSSara C. M. Stoof
Sara C. M. Stoof
HEHenrik Endeman
Henrik Endeman
Background: Treatment guidelines for acute respiratory distress syndrome (ARDS) recommend the use of high‐dose corticosteroids based on their anti‐inflammatory effects, yet the efficacy of this therapeutic strategy in patients with COVID‐19 related ARDS is inconclusive. To more thoroughly understand the mechanism of action for high‐dose corticosteroids in patients with COVID‐19‐related ARDS, we hypothesized that the reduction of inflammatory markers induced by high‐dose corticosteroids would reduce mortality (i.e., inflammation as a mediator). Design and Methods: In this retrospective cohort study, we included patients with COVID‐19‐related ARDS admitted to the intensive care unit (ICU) of an academic hospital in Rotterdam, the Netherlands between March 2020 and June 2022. High‐dose corticosteroids were defined as > 6 mg of dexamethasone/day or equivalent. Biomarkers included C‐reactive protein (CRP), d ‐dimer, ferritin, leukocyte count, interleukin‐6 (IL‐6), lactate dehydrogenase, and neutrophil‐to‐lymphocyte ratio (NLR). Using a causal mediation framework, we estimated the average mediation effect (AME) and % mediation for each biomarker, allowing to quantify the degree to which continuous levels of inflammatory markers mediate the association between receiving high‐dose corticosteroids and mortality. The models used in this framework accounted for time‐varying treatment/mediation with inverse probability of treatment weights, determined from the covariates PaO 2 /FiO 2 ratio, sex at birth, age, NLR, and ICU length of stay. Results: Of the 327 patients included, 122 (37.3%) received high‐dose corticosteroids. The risk of death was higher in patients who did vs. did not receive high‐dose corticosteroids [incidence rate = 0.54, 95% confidence interval (CI) = 0.42–0.71 and 0.21, 95% CI = 0.15–0.29/person‐month, respectively; p < 0.001]. This effect remained in most analyses accounting for time‐varying treatment/mediation. The association between high‐dose corticosteroids and mortality was reduced (i.e., mediated) with lower levels of CRP (AME = −0.006, 95% CI = −0.011, −0.002; %‐mediation = −82.0%), d ‐dimer (AME = −0.002, 95% CI = −0.005, −0.001; %‐mediation = −33.1%), and IL‐6 (AME = −0.002, 95% CI = −0.004, −0.001; %‐mediation = −25.5%). There was no evidence of mediation for other biomarkers. Conclusion: CRP, d ‐dimer, and IL‐6 mediated the association between high‐dose corticosteroids and mortality. When inflammation was reduced, the deleterious effect of high‐dose corticosteroids was eliminated.